Bullish & Foolish
Full TOI fundamentals All 466 on the Survival Watch

TOIStarling Oncology, Inc.

Is Starling Oncology struggling financially?

Yes, by its own account. Starling Oncology told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Reverse stock split

    Proposal At the Company’s 2025 annual meeting of stockholders, stockholders approved a proposal to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock if deemed appropriate by the Board (the “2025 Reverse Stock Split Proposal”).

    Form DEF 14A, filed 30 Apr 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 15months

    If the burn speeds up

    Empty by Sep 2027

  • 21months

    If it eases off

    Empty by Mar 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$41.1M

÷

Cash burned over the last 12 months

$27.8M

What Starling Oncology told the SEC

…months ended March 31, 2026, the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company had cash and cash equivalents of $ 30,280 and an accumulated deficit of $ 273,911 at March 31,…

Starling Oncology, Inc., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 20.2% share-count increase The company issued stock. Each share now owns 16.8% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Debt is large against the cash on hand while the business generates little to service it, which puts lenders ahead of shareholders in the queue.
  • Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt